SMYD2 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Oct 16, 2014
app pub date -
Jun 29, 2012
filing date -
Dec 2, 2011
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention arises from the discovery that the SMYD2 gene is both specifically over-expressed in cancer and involved in cancer cell survival. The present invention features methods for detecting or diagnosing the presence of or predisposition for developing cancer, using the SMYD2 gene as a diagnostic marker. The present invention further provides methods of screening for therapeutic substances useful in either or both of the treatment and prevention of cancer.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully